Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PLL012
MIFTS: 48

Pollen Allergy

Categories: Immune diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Pollen Allergy

About this section

MalaCards integrated aliases for Pollen Allergy:

Name: Pollen Allergy 12 15
Hay Fever 73

Classifications:

MalaCards categories:
Anatomical: Immune diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0060497
UMLS 73 C0018621
Sources

Summaries for Pollen Allergy

About this section
Disease Ontology : 12 A respiratory allergy triggered by pollen.

MalaCards based summary : Pollen Allergy, also known as hay fever, is related to esophagitis, eosinophilic, 1 and rhinitis, and has symptoms including coughing, snoring and tinnitus. An important gene associated with Pollen Allergy is CD164 (CD164 Molecule), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Cetirizine and Histamine have been mentioned in the context of this disorder. Affiliated tissues include eye, skin and testes, and related phenotypes are hematopoietic system and immune system

Wikipedia : 76 Allergic rhinitis, also known as hay fever, is a type of inflammation in the nose which occurs when the... more...

Sources

Related Diseases for Pollen Allergy

About this section

Diseases related to Pollen Allergy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 119)
# Related Disease Score Top Affiliating Genes
1 esophagitis, eosinophilic, 1 30.7 IL13 IL5
2 rhinitis 27.9 EPX ICAM1 IL13 IL4R IL5 RNASE3
3 allergic rhinitis 27.4 EPX ICAM1 IL13 IL4R IL5 RNASE3
4 asthma 25.2 ADRB2 CD79A EPX ICAM1 IL13 IL3
5 timothy grass allergy 11.1
6 loeffler endocarditis 10.7 IL5 RNASE3
7 cough variant asthma 10.7 IL5 RNASE3
8 autoimmune enteropathy 10.6 FOXP3 ICAM1
9 heterophyiasis 10.6 CD79A ICAM1
10 kimura disease 10.6 IL5 RNASE3
11 cellulitis 10.6 IL5 RNASE3
12 hymenolepiasis 10.6 CD79A ICAM1
13 rapidly progressive glomerulonephritis 10.5 CD79A ICAM1
14 chronic interstitial cystitis 10.5 CD79A RNASE3
15 nut allergy 10.5 FOXP3 IL5
16 acute proliferative glomerulonephritis 10.5 CD79A ICAM1
17 anisakiasis 10.5 CD79A RNASE3
18 amebiasis 10.5 CD79A ICAM1
19 maxillary sinusitis 10.5 CD79A RNASE3
20 hypersensitivity reaction type iii disease 10.5 CD79A ICAM1
21 cytokine deficiency 10.5 IL13 IL5
22 angioimmunoblastic lymphadenopathy with dysproteinemia 10.5 IL13 IL5
23 respiratory syncytial virus infectious disease 10.5 IL13 IL5
24 actinic prurigo 10.5 ICAM1 IL13
25 primary amebic meningoencephalitis 10.4 CD79A IL5
26 angiostrongyliasis 10.4 IL13 IL5
27 erythema multiforme 10.4 CD79A ICAM1
28 ascaris lumbricoides infection 10.4 IL13 IL5
29 anterior scleritis 10.4 CD79A IL5
30 eosinophilic meningitis 10.4 IL13 IL5
31 intestinal schistosomiasis 10.4 IL13 IL5
32 chronic eosinophilic pneumonia 10.4 ICAM1 IL5 RNASE3
33 penicillin allergy 10.4 IL13 IL4R
34 pustulosis palmaris et plantaris 10.4 CD79A IL5
35 chronic tic disorder 10.4 IL13 IL5
36 beta-lactam allergy 10.4 IL13 IL4R
37 seborrheic infantile dermatitis 10.4 IL3 IL5
38 chronic maxillary sinusitis 10.3 CD79A RNASE3
39 ulcerative stomatitis 10.3 CD79A FOXP3
40 hypereosinophilic syndrome, idiopathic 10.3 IL3 IL5
41 wells syndrome 10.3 IL5 RNASE3
42 sinusitis 10.3 IL4R IL5 RNASE3
43 night blindness, congenital stationary, type 1a 10.3 IL13 IL5
44 thymic dysplasia 10.3 CD79A FOXP3
45 autoimmune disease of endocrine system 10.3 FOXP3 ICAM1
46 churg-strauss syndrome 10.2 IL5 RNASE3
47 bullous skin disease 10.2 CD79A IL5
48 henoch-schoenlein purpura 10.2 CD79A ICAM1 RNASE3
49 enterobiasis 10.2 IL13 IL5
50 cow milk allergy 10.2 CD79A IL5 RNASE3

Graphical network of the top 20 diseases related to Pollen Allergy:



Diseases related to Pollen Allergy
Sources

Symptoms & Phenotypes for Pollen Allergy

About this section

UMLS symptoms related to Pollen Allergy:


coughing, snoring, tinnitus, sore throat, vertigo/dizziness, equilibration disorder, rhinorrhea

MGI Mouse Phenotypes related to Pollen Allergy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.56 ADRB2 CD79A EPX FOXP3 ICAM1 IL13
2 immune system MP:0005387 9.23 ADRB2 CD79A EPX FOXP3 ICAM1 IL13
Sources

Drugs & Therapeutics for Pollen Allergy

About this section

Drugs for Pollen Allergy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 172)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cetirizine Approved Phase 4,Phase 3,Phase 2,Not Applicable 83881-51-0 2678
2
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 75614-87-8, 51-45-6 774
3
Montelukast Approved Phase 4,Phase 3,Phase 2,Not Applicable 158966-92-8 5281040
4
Nitric Oxide Approved Phase 4 10102-43-9 145068 160954
5
Azelastine Approved Phase 4,Phase 3,Phase 2,Not Applicable 58581-89-8 2267
6
Fluticasone Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 90566-53-3 62924
7
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 299-42-3 9294
8
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
9
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
10
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 90-82-4 7028
11
Xylometazoline Approved, Investigational Phase 4,Not Applicable 526-36-3 5709
12
Loratadine Approved, Investigational Phase 4,Phase 3,Phase 2 79794-75-5 3957
13
Oxymetazoline Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1491-59-4 4636
14
Phenylephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 59-42-7 6041
15
Levocetirizine Approved Phase 4,Phase 3,Phase 2,Not Applicable 130018-77-8 1549000
16
Desloratadine Approved, Investigational Phase 4,Phase 3,Phase 2 100643-71-8 124087
17
Fexofenadine Approved, Investigational Phase 4,Phase 3,Phase 2 83799-24-0 3348
18
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
19
Promethazine Approved, Investigational Phase 4 60-87-7 4927
20
Tranilast Approved, Investigational Phase 4 53902-12-8 93543
21
Epinastine Approved, Investigational Phase 4,Phase 3,Phase 2 80012-43-7 3241
22
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
23
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
24
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
25 Anti-Allergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Histamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Histamine H1 Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Histamine H1 Antagonists, Non-Sedating Phase 4,Phase 3,Phase 2,Not Applicable
30
Histamine Phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-74-1 65513
31 Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
32 Hormones Phase 4,Phase 3,Phase 2,Not Applicable
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
34 Leukotriene Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
35 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Bronchodilator Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Lipoxygenase Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
42 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Antineoplastic Agents, Hormonal Phase 4
44 glucocorticoids Phase 4,Phase 3,Phase 2,Not Applicable
45 Methylprednisolone acetate Phase 4
46 Methylprednisolone Hemisuccinate Phase 4
47 mometasone furoate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Nasal Decongestants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Prednisolone acetate Phase 4
50 Prednisolone hemisuccinate Phase 4

Interventional clinical trials:

(show top 50) (show all 413)
# Name Status NCT ID Phase Drugs
1 Comparison of the Effect of Montelukast and Cetirizine on Allergic Inflammation in Children With Allergic Rhinitis Unknown status NCT00488176 Phase 4 montelukast;cetirizine;montelukast and cetirizine;placebo
2 POLlinosis and Exhaled Breath Temperature Unknown status NCT01785394 Phase 4 5 grass allergen extract
3 Immunological Mechanisms of Oralair® in Patients With Seasonal Allergic Rhinitis Unknown status NCT02014623 Phase 4 Control
4 Evaluating Factors Involved in Dymista's Superior Clinical Efficacy to Fluticasone Propionate in the Treatment of Seasonal Allergic Rhinitis Unknown status NCT02402465 Phase 4 Placebo;Fluticasone propionate;Fluticasone/Azelastine nasal spray
5 4"S" - Seasonal Symptoms Suppression Study Unknown status NCT02557269 Phase 4 Xylometazoline - intranasal application;Azelastine - intranasal application;Mometasone furoate - intranasal application;Hydroxyl-propyl-methyl cellulose powder - intranasal application;Bilastine 20 mg;Prednisolone 5 mg
6 Can we Help People With the Oral Allergy Syndrome Eat Fresh Fruit? Unknown status NCT01431859 Phase 4
7 Fluticasone Furoate Treatment of Daytime Somnolence and Cognitive Performance in Seasonal Allergic Rhinitis Completed NCT00997620 Phase 4 Fluticasone furoate Nasal Spray 110 mcg;Placebo
8 Efficacy and Safety of Lectranal® in Treatment of Seasonal Allergic Rhinitis Symptoms Completed NCT00460538 Phase 4
9 Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial Completed NCT00691665 Phase 4 Olopatadine HCL Nasal Spray, 0.6%;Fluticasone Propionate Nasal Spray, 50 mcg
10 A Randomized, Placebo Controlled Study to Determine the Efficacy and Speed of a Nasal Spray in Allergen Induced Seasonal Allergic Rhinitis Completed NCT00561717 Phase 4 Azelastine and placebo;Loratadine and Placebo;Cetirizine and Placebo;Placebo and Placebo (spray and Tablet)
11 A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis Completed NCT00653224 Phase 4 levocetirizine dihydrochloride;placebo
12 A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis Completed NCT00621959 Phase 4 levocetirizine dihydrochloride;placebo
13 Preference for Clarinex Tablets vs Allegra Tablets in Patients With Seasonal Allergies (P03178) Completed NCT00794768 Phase 4 desloratadine 5 mg;fexofenadine
14 Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03179) Completed NCT00794248 Phase 4 desloratadine 5 mg;fexofenadine
15 Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03177) Completed NCT00783133 Phase 4 Desloratadine 5 mg;fexofenadine
16 Single-Center, Double-Blind, Randomized , Parallel Study Comparing Onset of Action, Efficacy & Safety of a Single-Dose of Fexofenadine HCl 180 mg vs Montelukast Na 10 mg & Placebo in Treating Seasonal Allergic Rhinitis Subjects in an Allergen Exposure Uni Completed NCT00637611 Phase 4 Fexofenadine HCl
17 Mometasone Furoate on Sleep Disturbances in Subjects With Seasonal Allergic Rhinitis (Study P04608) (COMPLETED) Completed NCT00358527 Phase 4 Mometasone Furoate Nasal Spray (MFNS)
18 Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR) (Study P04054) Completed NCT00783146 Phase 4 desloratadine;fexofenadine;placebo
19 Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR)(Study P04053)(COMPLETED) Completed NCT00783211 Phase 4 desloratadine;fexofenadine;placebo
20 Comparison of the Effects of Desloratadine and Placebo in the Relief of Nasal Symptom Scores in Subjects With Seasonal Allergic Rhinitis to Cypress Pollen (Study P02836) Completed NCT00867191 Phase 4 Placebo;Desloratadine
21 This Study Contains an Active Drug Treatment Group With Mometasone Furoate Nasal Spray and a Placebo (Dummy) Treatment Group for Seasonal Allergic Rhinitis (SAR). (Study P05073)(COMPLETED) Completed NCT00491504 Phase 4 Mometasone Furoate Nasal Spray
22 Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine HCl Syrup vs. Loratadine Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR) Completed NCT02932774 Phase 4 Cetirizine;Loratadine
23 Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid Completed NCT00845195 Phase 4 Olopatadine HCl Nasal Spray, 0.6%;Azelastine HCl Nasal Spray, 0.1%
24 Vitamin D Plus Fluticasone Propionate Completed NCT01103934 Phase 4 Vitamin D3;Placebo;Fluticasone Propionate
25 Efficacy of 2LALERG (Homeopathic Drug) in Allergic Rhinitis Related to Grass Pollen Completed NCT02690935 Phase 4 2LALERG;Placebo
26 Study of Nasal Symptom Relief and Side Effects in Hayfever Patients Treated With Aerius (Desloratadine)(P03442) Completed NCT00805584 Phase 4 desloratadine
27 POPULAR (Preference Of Patient Using Levocetirizine in Allergic Rhinitis) Completed NCT00160537 Phase 4 Levocetirizine
28 A Study of Onset of Action of Loratadine and Fexofenadine in Participants With Seasonal Allergic Rhinitis (P08712) Completed NCT01469234 Phase 4 loratadine;fexofenadine;placebo to loratadine;placebo to fexofenadine
29 Effects of Sublingual Immunotherapy on Grasspollen Allergy Completed NCT00150514 Phase 4 Oralgen
30 A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis Completed NCT01916226 Phase 4 FPNS;FPNS Placebo;Cetirizine;Cetirizine Placebo
31 To Determine if Diphenhydramine Works for Nasal Congestion at Two Different Doses Completed NCT00648973 Phase 4 Diphenhydramine 50 mg;Diphenhydramine 25 mg;Pseudoephedrine 120 mg
32 Comparison of Perennial and Preseasonal Subcutaneous Immunotherapy Completed NCT01555736 Phase 4 grass (80%) and rye (20%) pollens allergoids
33 Effectiveness Of Therapy With A Thermal Water Nasal Aerosol In Children With Seasonal Allergic Rhinitis Completed NCT01326247 Phase 4
34 Efficacy and Safety of Levocetirizine and Fexofenadine in Reducing Symptoms of Seasonal Allergic Rhinitis Completed NCT00542607 Phase 4 levocetirizine dihydrochloride
35 Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms Completed NCT00891436 Phase 4 Fluticasone furoate nasal spray;Placebo nasal spray
36 Allergic Rhinitis Changes the Sinus Microbiome Completed NCT01852513 Phase 4 QNASL;Placebo nasal spray
37 MP-AzeFlu Allergen Chamber - Onset of Action Study Completed NCT03004131 Phase 4 Azelastine hydrochloride + fluticasone propionate nasal spray;Placebos;fluticasone propionate nasal spray + loratadine
38 Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy Symptoms Completed NCT01007253 Phase 4 PL nasal spray;fluticasone furoate (FF);PL eye drops;olopatadine (OLO)
39 Intranasal Steroids and the Nasal Ocular Response Completed NCT00473915 Phase 4 fluticasone furoate
40 Compare the Efficacy of Levocetirizine and Montelukast to Placebo in Reducing SAR Symptoms in Ragweed Sensitive Subjects Completed NCT00295022 Phase 4 Levocetirizine
41 Single Center, Randomized, Double-Blind,Crossover Study Comparing Effects Of Single-Dose Fexofenadine HCl 180 mg, Cetirizine 10 mg, and Placebo on Cognitive Performance in Naval Flight Personnel Completed NCT00637455 Phase 4 fexofenadine HCl
42 Regulatory Lymphocytes in Patients Treated With Specific Immunotherapy Completed NCT01475188 Phase 4 Allergovit
43 Comparator Study Evaluating Patient Preference Of FFNS vs. FPNS Completed NCT00539006 Phase 4 FPNS;FFNS;placebo FPNS;placebo FFNS
44 Tolerability of Grazax in Patients With Hayfever in Real Life Settings Completed NCT01433510 Phase 4 Grazax
45 Comparator Study Evaluating Patient Experience And Preference Of FFNS vs. FPNS Completed NCT00519636 Phase 4 FPNS;FFNS;placebo FFNS;placebo FPNS
46 Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR) Completed NCT00818805 Phase 4 Olopatadine 0.1%;Tranilast 0.5%;Placebo (Olopatadine);Placebo (Tranilast)
47 Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine Completed NCT00502775 Phase 4 fluticasone furoate, fexofenadine
48 Effects of Hypertonic Saline Solution (NACL 3%+NAHCO3) on Nasal Inflammation in Children With AR. RinASol- Pilot Study Completed NCT02729012 Phase 4 hypertonic saline solution (NACL 3%+NAHCO3)
49 Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine Completed NCT00435461 Phase 4 Fluticasone furoate and fexofenadine
50 Study Of Patients With Allergic Rhinitis And Asthma Completed NCT00296530 Phase 4 fluticasone propionate/salmeterol;fluticasone propionate;montelukast

Search NIH Clinical Center for Pollen Allergy

Inferred drug relations via UMLS 73 / NDF-RT 51 :
Sources

Genetic Tests for Pollen Allergy

About this section
Sources

Anatomical Context for Pollen Allergy

About this section

MalaCards organs/tissues related to Pollen Allergy:

41
Eye, Skin, Testes, Bone, Neutrophil, T Cells, Lymph Node
Sources

Publications for Pollen Allergy

About this section

Articles related to Pollen Allergy:

(show top 50) (show all 69)
# Title Authors Year
1
Long-term effect of monophosphoryl lipid A adjuvanted specific immunotherapy in patients with grass pollen allergy. ( 29562801 )
2018
2
Thunderstorm asthma: controlling (deadly) grass pollen allergy. ( 29437642 )
2018
3
Impacts of long-term ragweed pollen load and other potential risk factors on ragweed pollen allergy among schoolchildren in Hungary. ( 29936806 )
2018
4
Cypress pollen allergy is responsible for two distinct phenotypes of allergic rhinitis different from other pollinosis. ( 29350019 )
2018
5
Ragweed Pollen Allergy: Burden, Characteristics, and Management of an Imported Allergen Source in Europe. ( 29788026 )
2018
6
Lolium perenne peptides for treatment of grass pollen allergy: AA randomized, double-blind, placebo-controlled clinical trial. ( 29030102 )
2018
7
Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope-based grass pollen allergy vaccine with allergen extract-based vaccines. ( 28576673 )
2017
8
Management of Grass Pollen Allergy with 5-Grass Pollen Tablet: Results of a 2-Year Real-Life Study. ( 28455783 )
2017
9
Efficacy of a leukotriene receptor antagonist for pediatric cedar pollen allergy complicated by asthma. ( 28928804 )
2017
10
Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. ( 28689794 )
2017
11
Natural protective immunity against grass pollen allergy is maintained byA a diverse spectrum of response types. ( 28867457 )
2017
12
The current overuse and misuse of meta-analyses on sublingual immunotherapy: the case of grass pollen allergy. ( 27922912 )
2017
13
Association of eosinophilic esophagitis and food pollen allergy syndrome. ( 27856094 )
2017
14
Involvement of cross-reactive carbohydrate determinants-specific IgE in pollen allergy testing. ( 28154803 )
2017
15
Patching it together: epicutaneous vaccination with heat-labile Escherichia coli toxin against birch pollen allergy. ( 27716934 )
2017
16
Molecular cloning of plane pollen allergen PlaA aA 3 and its utility as diagnostic marker for peach associated plane pollen allergy. ( 26892183 )
2016
17
Efficacy and effectiveness of sublingual immunotherapy for grass pollen allergy: Reply to the letter of Marcucci F. ( 26778720 )
2016
18
Climate Change and Future Pollen Allergy in Europe. ( 27557093 )
2016
19
Biological Effects of Cloth Containing Specific Ore Powder in Patients with Pollen Allergy. ( 27660220 )
2016
20
Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B Infection. ( 27568223 )
2016
21
Persistence of the IgE repertoire in birch pollen allergy. ( 27001158 )
2016
22
Mould and grass pollen allergy as risk factors for childhood asthma in Zaragoza, Spain. ( 27255475 )
2016
23
Urtica dioica pollen allergy: Clinical, biological, and allergomics analysis. ( 27788883 )
2016
24
Pollen information consumption as an indicator of pollen allergy burden. ( 26373744 )
2016
25
A biology-driven receptor model for daily pollen allergy risk in Korea based on Weibull probability density function. ( 27387542 )
2016
26
Efficacy and effectiveness of sublingual immunotherapy for grass pollen allergy. ( 27012472 )
2016
27
Relevance of a 5-grass sublingual tablet for immunotherapy of patients with grass pollen allergy in North America. ( 26813047 )
2016
28
Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy. ( 27650868 )
2016
29
The Smartphone: A Novel Diagnostic Tool in Pollen Allergy? ( 27326995 )
2016
30
Oocyst-Derived Extract of Toxoplasma Gondii Serves as Potent Immunomodulator in a Mouse Model of Birch Pollen Allergy. ( 27149118 )
2016
31
Establishment and characterization of a novel murine model for pollen allergy. ( 26011678 )
2015
32
Epigenetic Regulation Analyses of FOXP3 in Olive Pollen Allergy. ( 26182692 )
2015
33
Oral Administration of Lipopolysaccharide of Acetic Acid Bacteria Protects Pollen Allergy in a Murine Model. ( 26168494 )
2015
34
Effects of the Subaleurone Layer of Rice on Macrophage Activation and Protection of Pollen Allergy in a Murine Model. ( 26168488 )
2015
35
Molecular evolution of hypoallergenic hybrid proteins for vaccination against grass pollen allergy. ( 25786690 )
2015
36
Eucalyptus pollen allergy and asthma in children: a cross-sectional study in South-East Queensland, Australia. ( 25938684 )
2015
37
Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy. ( 25441634 )
2015
38
Therapeutic targets for olive pollen allergy defined by gene markers modulated by Ole e 1-derived peptides. ( 25553522 )
2015
39
Eosinophilic esophagitis in a girl with pollen allergy who showed trachealization. ( 25698278 )
2015
40
Concentrated protein body product derived from rice endosperm as an oral tolerogen for allergen-specific immunotherapy--a new mucosal vaccine formulation against Japanese cedar pollen allergy. ( 25774686 )
2015
41
Efficacy but not effectiveness of sublingual immunotherapy for grass pollen allergy: Time to avoid waste in health-care expenditure. ( 26377975 )
2015
42
Plant pollen content in the air of Lublin (central-eastern Poland) and risk of pollen allergy. ( 25528903 )
2014
43
Internet searches and allergy: temporal variation in regional pollen counts correlates with Google searches for pollen allergy related terms. ( 25131951 )
2014
44
Association between a low IgE response to Phl p 5 and absence of asthma in patients with grass pollen allergy. ( 24308506 )
2013
45
Pollen allergy and eosinophilic esophagitis. ( 22798123 )
2012
46
Can component-based microarray replace fluorescent enzimoimmunoassay in the diagnosis of grass and cypress pollen allergy? ( 21749500 )
2011
47
Eosinophilia in conjunctival tear fluid among patients with pollen allergy. ( 21875549 )
2011
48
Validation of basophil CD164 upregulation for pollen allergy diagnosis. ( 20872290 )
2010
49
[Relationship between IgE antibodies to recombinant allergens rBet v 1 and rBet v 2 and food causing oral allergy syndrome in cases of birch-pollen allergy]. ( 20845708 )
2010
50
Component-resolved diagnosis of pollen allergy based on skin testing with profilin, polcalcin and lipid transfer protein pan-allergens. ( 19877313 )
2009
Sources

Variations for Pollen Allergy

About this section
Sources

Expression for Pollen Allergy

About this section
Search GEO for disease gene expression data for Pollen Allergy.
Sources

Pathways for Pollen Allergy

About this section

Pathways related to Pollen Allergy according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.72 CD79A EPX ICAM1 IL13 IL3 IL4R
2
Cytokine Signaling in Immune system 66
Show member pathways
 13.08 ICAM1 IL13 IL3 IL4R IL5
3
Pathways in cancer 37
12.56 IL13 IL3 IL4R IL5
4
Regulation of IFNA signaling 66
Show member pathways
 12.35 IL13 IL3 IL4R IL5
5
Immune response Fc epsilon RI pathway 22
Show member pathways
 12.33 CD79A IL13 IL3 IL5
6
Th17 cell differentiation 37
Show member pathways
 12.09 FOXP3 IL13 IL4R IL5
7
Allograft rejection 1 37
Show member pathways
 11.97 EPX FOXP3 ICAM1 IL13 IL3 IL4R
8
Interleukin-4 and 13 signaling 66
11.74 ICAM1 IL13 IL4R
9
Immune response IFN gamma signaling pathway 22
Show member pathways
 11.73 ICAM1 IL13 IL3 IL4R IL5
10
Hematopoietic cell lineage 37
11.64 IL3 IL4R IL5
11
Glucocorticoid receptor regulatory network 1
11.52 ICAM1 IL13 IL5
12
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.52 CD164 CD79A IL3 IL5
13
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.46 FOXP3 IL3 IL5
14
Inflammatory Response Pathway 1
11.09 IL4R IL5
15
Development and heterogeneity of the ILC family 1
11.06 IL13 IL5
16
OX40 Pathway 64
10.96 IL13 IL5
17
Th2 Differentiation Pathway 65
10.92 FOXP3 IL13 IL4R IL5
18
Cytokines and Inflammatory Response 1
10.91 IL13 IL3 IL5
Sources

GO Terms for Pollen Allergy

About this section

Cellular components related to Pollen Allergy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 CD164 EPX IL13 IL3 IL4R IL5
2 extracellular space GO:0005615 9.17 EPX ICAM1 IL13 IL3 IL4R IL5

Biological processes related to Pollen Allergy according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.54 ICAM1 IL3 IL5
2 positive regulation of B cell proliferation GO:0030890 9.49 IL13 IL5
3 negative regulation of endothelial cell apoptotic process GO:2000352 9.48 ICAM1 IL13
4 positive regulation of interleukin-4 production GO:0032753 9.46 EPX FOXP3
5 positive regulation of macrophage activation GO:0043032 9.43 IL13 IL4R
6 negative regulation of interleukin-10 production GO:0032693 9.4 EPX FOXP3
7 immune response GO:0006955 9.35 CD164 IL13 IL3 IL4R IL5
8 positive regulation of mast cell degranulation GO:0043306 9.32 IL13 IL4R
9 positive regulation of immunoglobulin production GO:0002639 9.26 IL13 IL4R
10 negative regulation of interleukin-5 production GO:0032714 9.16 EPX FOXP3
11 cytokine-mediated signaling pathway GO:0019221 9.02 ICAM1 IL13 IL3 IL4R IL5

Molecular functions related to Pollen Allergy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.8 IL13 IL3 IL5
Sources

Sources for Pollen Allergy

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....